Get the Stockscreener App
42.66
0.95%
0.40
After Hours:
42.66
Kodiak Sciences Inc stock is traded at $42.66, with a volume of 972.99K.
It is up +0.95% in the last 24 hours and up +5.00% over the past month.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
See More
Previous Close:
$42.26
Open:
$42.95
24h Volume:
972.99K
Relative Volume:
0.92
Market Cap:
$2.65B
Revenue:
-
Net Income/Loss:
$-229.97M
P/E Ratio:
-9.8672
EPS:
-4.3234
Net Cash Flow:
$-136.51M
1W Performance:
-6.10%
1M Performance:
+5.00%
6M Performance:
+139.26%
1Y Performance:
+767.07%
1-Day Range:
$42.25
$44.40
1-Week Range:
$41.89
$46.59
52-Week Range:
$2.8101
$47.84
Kodiak Sciences Inc Stock (KOD) Company Profile
Name
Kodiak Sciences Inc
Sector
Industry
Phone
650-281-0850
Address
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
42.66 | 2.63B | 0 | -229.97M | -136.51M | -4.3234 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-25-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Sep-22-25 | Initiated | Jefferies | Buy |
| Aug-14-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| Dec-11-23 | Resumed | Goldman | Sell |
| Nov-17-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Jul-25-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jul-25-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jul-24-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-15-22 | Initiated | CapitalOne | Overweight |
| Aug-02-22 | Downgrade | Citigroup | Neutral → Sell |
| Feb-24-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-11-22 | Initiated | Goldman | Buy |
| Feb-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-12-21 | Initiated | Evercore ISI | Outperform |
| Mar-01-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Nov-30-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-03-20 | Initiated | Goldman | Buy |
| Feb-18-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-06-20 | Initiated | SunTrust | Buy |
| Jan-08-20 | Initiated | ROTH Capital | Buy |
| Jan-03-20 | Initiated | Jefferies | Buy |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-20-19 | Initiated | Chardan Capital Markets | Buy |
| Oct-29-18 | Initiated | Barclays | Overweight |
| Oct-29-18 | Initiated | BofA/Merrill | Buy |
| Oct-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Kodiak Sciences Inc Stock (KOD) Latest News
Kodiak Sciences (KOD) up 2% since last earnings report: Can it continue? - MSN
Kodiak Sciences Inc. $KOD Stock Holdings Decreased by RIA Advisory Group LLC - MarketBeat
Eye drug data from Taiwan cohort backs Kodiak Phase 3 expansion - Stock Titan
Kodiak Sciences Presents Pipeline Advances and KSI-101 Clinical Data At Scientific Conferences - marketscreener.com
Kodiak Sciences stock is surging Friday: What's driving the action? - MSN
Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
US stocks: Kodiak Sciences shares soar 68% after eye drug succeeds in late-stage study - MSN
Kodiak Q4 loss wider than expected, pipeline development in focus - MSN
Diabetic Retinopathy Pipeline Set for Transformational Breakthroughs by 2026 with 55+ Therapies expanding Clinical Innovation from Kodiak Sciences, Regenxbio, Adverum Biotechnologies | DelveInsight - Barchart.com
Diabetic Retinopathy Pipeline Set for Transformational - openPR.com
BlackRock (KOD) holds 3.27M shares, a 5.3% stake in Kodiak Sciences (KOD) - Stock Titan
Kodiak climbs on late-stage trial win for diabetic retinopathy therapy - MSN
Kodiak Sciences Reports Positive Trial Results for Diabetic Retinopathy - HarianBasis.co
Kodiak Sciences Inc (KOD): What’s the Chance of Success for Zenkuda? - Insider Monkey
KOD Kodiak Sciences Inc reports narrow Q4 2025 EPS beat, shares drop 3.74 percent on weak investor sentiment.Viral Trade Signals - Xã Thanh Hà
[ARS] Kodiak Sciences Inc. SEC Filing - Stock Titan
Executive pay and 2026 director vote at Kodiak Sciences (NASDAQ: KOD) - Stock Titan
Is Kodiak Sciences (KOD) stock stronger than industry leaders (-1.28%) 2026-04-22Diversification - Cổng thông tin điện tử tỉnh Lào Cai
10 Best 52-Week High US Stocks to Buy - Insider Monkey
Kodiak Sciences Inc. (NASDAQ:KOD) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Why Kodiak Sciences Stock Is On The Move - TipRanks
Kodiak Sciences Inc stock hits 52-week high at $46.69 By Investing.com - Investing.com Australia
Kodiak Sciences (NASDAQ:KOD) Hits New 12-Month HighWhat's Next? - MarketBeat
Kodiak Sciences Inc stock hits 52-week high at $46.69 - Investing.com
Kodiak Sciences (KOD) reports Q4 EPS of ($1.05) - MSN
Kodiak Sciences (NASDAQ:KOD) Stock Price Up 9.8%What's Next? - MarketBeat
Kodiak Sciences KOD Stock Soars On Phase 3 Win - timothysykes.com
Russell 2000 Rips To Record High — Here Are The Top Small Cap Gainers - Benzinga
Kodiak Sciences (NASDAQ: KOD) CFO exercises options, now holds 211,930 shares - Stock Titan
Kodiak Sciences (NASDAQ:KOD) Signals Behind Surge Points To Momentum - Kalkine Media
Kodiak Sciences Inc. (NASDAQ:KOD) Short Interest Up 39.8% in March - MarketBeat
Kodiak Sciences (KOD) Stock: Downtrend Signals? (Loses Ground) 2026-04-15Overvalued Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Kodiak Sciences Stock Price Drops 5.5% - National Today
Kodiak Sciences (NASDAQ:KOD) Stock Price Down 5.5%Should You Sell? - MarketBeat
Kodiak Sciences shares jump on encouraging Phase 3 trial results - MSN
Why Kodiak Sciences Stock Is Surging Higher Today - TipRanks
Kodiak Sciences (KOD) climbs 75% on stellar clinical results - MSN
Kodiak Sciences stock hits 52-week high at $45.73 By Investing.com - Investing.com Australia
Kodiak Sciences Stock Soars to New 52-Week High - National Today
Kodiak Sciences Inc Stock (KOD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):